Skybiotech Healthcare Limited (KAPILCO) — shareholding pattern, promoter holding, financials and share price
About Skybiotech Healthcare Limited (KAPILCO)
Skybiotech Healthcare Limited operates in the Other Textile Products industry, within the Textiles sector. It trades on the NSE as KAPILCO and on the BSE under scrip code 512036. Its ISIN is INE393H01016.
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals [1]
Kapil Cotex Limited, established in 1983, specializes in spinning, weaving, and finishing textiles but shifted away from its primary operations recently.
The company has diversified into providing consultancy and assistance for selling goods of foreign clients, significantly earning through brokerage and consultancy income.
Listed peers in Other Textile Products: Gujarat Cotex Ltd, Sihora Industries Ltd, Jaihind Industries Ltd, Katare Spinning Mills Ltd, Classic Filaments Ltd, Sparkle Gold Rock Ltd.
Valuation & Returns
At ₹137 a share, Skybiotech Healthcare Limited (KAPILCO) was valued at a price-to-earnings ratio of -27.86x against an industry P/E of 32.15x and a price-to-book of 3.87x on a book value of ₹41.75 per share. Solomo computes return on equity of -13.97% and return on capital employed of -10.03% from filed results.
- P/E
- -27.86x
- Industry P/E
- 32.15x
- P/B
- 3.87x
- EPS (TTM)
- ₹-9.49
- Book value / share
- ₹41.75
- ROE
- -13.97%
- ROCE
- -10.03%
- ROA
- -5.71%
- Debt / equity
- 1.05x
- Dividend yield
- 0%
- EBITDA margin
- -16.48%
- 52-week range
- ₹116.45 – ₹237.3
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Skybiotech Healthcare Limited (KAPILCO) reported revenue of ₹7.1 crore, net profit of ₹-1.12 crore and earnings per share of ₹-5.85. That compares with revenue of ₹6.96 crore and net profit of ₹-2.37 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.83 crore and net profit ₹-0.3 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 0 | 6.96 | 7.1 |
| Net profit (₹ cr) | 1.54 | -2.37 | -1.12 |
| EPS (₹) | 8.04 | -12.38 | -5.85 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Profit growth | 33.55% | - | - | -96.10% |
| Stock price CAGR | - | 26% | 18% | -39% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.48% of Skybiotech Healthcare Limited (KAPILCO) (unchanged from the previous quarter). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: GANESH SHIVPRASAD LAHOTI 4.44%, SANGITA ASHISH RATHI 3.26%, KAUSTUBH ASHISH RATHI 3.26%, SMITA SHIVPRASAD LAHOTI 2.09%, ALKA PRAVIN JOSHI . 1.96%, RAKESH SATYA NARAYAN RATHI 1.39%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.48% | - | - | - | 36.52% |
| Mar 2026 | 63.48% | - | - | - | 36.52% |
| Dec 2025 | 63.48% | - | - | - | 36.52% |
| Sep 2025 | 63.48% | - | - | - | 36.52% |
| Jun 2025 | 63.48% | - | - | - | 36.52% |
| Mar 2025 | 63.48% | - | - | - | 36.52% |
| Dec 2024 | 62.71% | - | - | - | 37.29% |
| Sep 2024 | 62.71% | - | - | - | 37.29% |